Cancer screening through a multi-analyte serum biomarker panel during health check-up examinations: Results from a 12-year experience

Clinica Chimica Acta

Volumn 450, Issue , 2015, Pages 273-276

  Wen, Ying Hao ^a   Chang, Pi Yueh ^a,b   Hsu, Chen Ming ^a   Wang, Hsin Yao ^a   Chiu, Cheng Tang ^a   Lu, Jang Jih ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Biomarker; Cancer screening; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; PROSTATE SPECIFIC ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; BREAST CANCER; CANCER CLASSIFICATION; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MOUTH CANCER; NEOPLASM; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TAIWANESE; UTERINE CERVIX CANCER; BLOOD; EARLY CANCER DIAGNOSIS; MASS SCREENING; MIDDLE AGED; NEOPLASMS; PHYSICAL EXAMINATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASMS; PHYSICAL EXAMINATION; YOUNG ADULT;

EID: 84941793728     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.09.004     Document Type: Article

References (19)

1. Duffy M.J. Tumor markers in clinical practice: a review focusing on common solid cancers. Med. Princ. Pract.: Int J. Kuwait Univ. Health Sci. Cent. 2013, 22(1):4-11.
2. van Haaften-Day C., Shen Y., Xu F., Yu Y., Berchuck A., Havrilesky L.J., et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001, 92(11):2837-2844.
3. He C.Z., Zhang K.H., Li Q., Liu X.H., Hong Y., Lv N.H. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol. 2013, 13:87.
4. Zhang P., Zou M., Wen X., Gu F., Li J., Liu G., et al. Development of serum parameters panels for the early detection of pancreatic cancer. Int. J. Cancer 2014, 134(11):2646-2655.
5. Tsao K.C., Wu T.L., Chang P.Y., Hong J.H., Wu J.T. Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers. J. Clin. Lab. Anal. 2006, 20(2):42-46.
6. Cancer Registry Annual Report, 2011 Taiwan 2014, Health Promotion Administration Ministry of Health and Welfare, Taiwan.
7. Frank S.A. Dynamics of Cancer: Incidence, Inheritance, and Evolution 2007, Princeton University Press. 1st ed.
8. Cavadas V., Osorio L., Sabell F., Teves F., Branco F., Silva-Ramos M. Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur. Urol. 2010, 58(4):551-558.
9. Zhao R., Huang Y., Cheng G., Liu J., Shao P., Qin C., et al. Developing a follow-up strategy for patients with PSA ranging from 4 to 10ng/ml via a new model to reduce unnecessary prostate biopsies. PLoS One 2014, 9(9).
10. Lok A.S., Sterling R.K., Everhart J.E., Wright E.C., Hoefs J.C., Di Bisceglie A.M., et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010, 138(2):493-502.
11. Wallner L.P., Jacobsen S.J. Prostate-specific antigen and prostate cancer mortality: a systematic review. Am. J. Prev. Med. 2013, 45(3):318-326.
12. Duffy M.J. PSA in screening for prostate cancer: more good than harm or more harm than good?. Adv. Clin. Chem. 2014, 66:1-23.
13. Chen Y.-Y., Chen T.-H., Su M.-Y., Ning H.-C., Kuo C.-J., Lin W.-P., et al. Accuracy of immunochemical fecal occult blood test for detecting colorectal neoplasms in individuals undergoing health check-ups. Adv. Dig. Med. 2014, 1(3):74-79.
14. Duffy M.J., van Rossum L.G., ST v.T., Malminiemi O., Sturgeon C., Lamerz R., et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int. J. Cancer 2011, 128(1):3-11.
15. Kanne J.P. Screening for lung cancer: what have we learned?. AJR Am. J. Roentgenol. 2014, 202(3):530-535.
16. Manser R., Lethaby A., Irving L.B., Stone C., Byrnes G., Abramson M.J., et al. Screening for lung cancer. Cochrane Database Syst. Rev. 2013, 6.
17. Brocklehurst P., Kujan O., LA O.'.M., Ogden G., Shepherd S., Glenny A.M. Screening programmes for the early detection and prevention of oral cancer. Cochrane Database Syst. Rev. 2013, 11.
18. Pan H.B., Wong K.F., Yang T.L., Hsu G.C., Chou C.P., Huang J.S., et al. The outcome of a quality-controlled mammography screening program: experience from a population-based study in Taiwan. J. Chin. Med. Assoc. 2014, 77(10):531-534.
19. Freimanis R.I., Yacobozzi M. Breast cancer screening. N. C. Med. J. 2014, 75(2):117-120.